Research
Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) cause rapid, significant loss of facial and body subcutaneous fat, leading to skin laxity, volume loss, and accelerated facial aging that requires proactive, multimodal aesthetic intervention.
If you are taking Ozempic or Mounjaro, expect your face to lose volume and your skin to sag. Don't wait until you look 'old' to act. Start aesthetic treatments (like fillers or skin tightening) early in your weight loss journey to maintain your shape and youthfulness.
ModerateSupportsMEDIUM confidence
Данные пациенты вместе с потерей веса, отмечают дряблость, атонию кожи, снижение тонуса, выраженные морщины, потерю объема мягких тканей и выглядят на 5 лет старше своего фактического возраста.
Why this rating
Based on a literature review and consensus statements (Delphi study), not a primary RCT.
Source
Patient support during GLP‑1 arGLP‑1 therapy: practical solutions for cosmetologists
I. A. Akhmedbaeva et al. · Medical alphabet · 2025
DOI 10.33667/2078-5631-2025-23-7-10
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →